—Interim Assessment Anticipated in Second Half of 2020— SAN FRANCISCO–(BUSINESS WIRE)–OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced initiation of its PREVAIL trial, a Phase 2...
– Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – – Initial data to be presented on February 13 at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers...
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical...
Part 2 will dose ~150 patients with TLC590, bupivacaine, or placebo Primary endpoint: AUC0-72 on numerical pain rating scale Enrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan , Jan. 08, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq:...
– Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer — — Marks expansion of lead product candidate avasopasem manganese into second radiation toxicity indication —...
Email
Text